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protein restriction slows the progression of kidney disease delay-
ing the dialysis treatment. The cost of treatment of end-stage
renal disease is high and increases with age. Therefore, delaying
the start of renal replacement therapy with hemodialysis and
improving the patient’s quality of life are two primary goals
justifying the use of protein-restricted diets. The aim of the study
was to evaluate the economic impact of a low-protein diet (0.6 gr
proteins/kg, body weight/day) with the intent of delay the hae-
modialysis treatment in patients with advanced chronic-renal-
failure. METHODS: The study was a naturalistic, longitudinal
retrospective Cost of Treatment study. Patients were enrolled
during the 2005 and followed up until 2007 or the beginning of
haemodialysis treatment. Direct health care resources attribut-
able to disease management (drugs, ambulatory care, day case
treatments, hospitalizations, specialist visits, diagnostics and
laboratory exams) were quantiﬁed using National Health Service
(NHS) tariffs expressed in Euro 2008. NHS perspective was
adopted. Health-related quality of life information were also
collected using SF-36 questionnaire at the enrolment and at the
end of the observation period. RESULTS: We enrolled 30
patients (males 60%, mean age of 56.5  13.9 y.o.) from the
Nephrology Department of the University “Federico II” of
Naples, with a mean follow-up of 12.7  7.5 months. The
average monthly cost of care was €1075.6  925.2 per patient,
mainly because of hospitalization which represented the 45.0%
of the expenses. SF-36 results showed a quality of life stable
during the observation period and quite similar to the general
population. CONCLUSIONS: This is the ﬁrst study evaluating
the economic impact of law-protein diet in patients with CRF in
Italy. The protein-restricted diets helps to delay initiation of
hemodialysis sessions, which substantially increase treatment
costs and negatively impacts quality of life.
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OBJECTIVES: The aim of this study was to assess the cost-
effectiveness of solifenacin (5 mg/10 mg) relative to tolterodine
ER 4 mg in the treatment of patients with overactive bladder
(OAB), from the perspective of the UK (NHS) health care system.
METHODS: This was a cost-utility analysis based on a one-year
decision-tree model. A systematic review and meta-analysis of
efﬁcacy data was performed to obtain estimates for clinical effec-
tiveness. The beneﬁts of treatment were measured according to
resolution of OAB symptoms and subsequent improvement in
health-related quality of life (HRQoL). Treatment success was
deﬁned separately for urgency, frequency and incontinence. Deﬁ-
nitions of treatment success were no urge episodes, eight or fewer
micturitions and no incontinence episodes per 24 hours respec-
tively. Incremental cost-effectiveness ratios (ICERs) were esti-
mated separately for each symptom. HRQoL values were taken
from published sources. Treatment persistence data and data for
the proportion of solifenacin patients receiving the higher dose,
10-mg formulation were obtained from the DIN-LINK database.
The analysis was undertaken from the perspective of the UK
NHS and included costs directly associated with the treatment of
OAB, i.e. cost of antimuscarinics, GP consultations and consul-
tations in an outpatient clinic; cost data was taken from NHS
published sources (at 2007/2008 prices). Resource utilisation
was based on expert opinion. RESULTS: ICERs fell below
£15,000/QALY in all analyses: £6,406/QALY, £9,065/QALY and
£14,374/QALY for urgency, frequency and incontinence out-
comes, respectively. ICERs remained below the threshold of
£30,000/QALY throughout univariate sensitivity analyses.
CONCLUSIONS: Treatment with solifenacin 5 mg/10 mg is
likely to be a cost-effective treatment strategy relative to toltero-
dine ER 4 mg in the UK healthc are setting.
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OBJECTIVES: The aim of this study was to assess the cost-
effectiveness of solifenacin (5 mg/10 mg) relative to fesoterodine
(4 mg/8 mg) for OAB, from the perspective of the UK (NHS)
health care system. METHODS: A cost-utility analysis was
undertaken using a one-year decision-tree model. Estimates for
clinical effectiveness were obtained from a systematic review
and meta-analysis. Treatment success was deﬁned separately for
urgency, frequency and incontinence. Deﬁnitions of treatment
success were no urgency episodes, eight or fewer micturitions and
no incontinence episodes per 24 hours. Incremental cost-
effectiveness ratios (ICERs) were estimated separately for each
symptom. Treatment persistence rates for solifenacin and the
percentage of patients requiring the higher-dose formulation of
solifenacin were taken from the DIN-LINK database. In the
absence of these data for fesoterodine, in the base case analysis
treatment persistence and the percentage of patients requiring
the higher dose formulation of fesoterodine were assumed to be
equal to that for solifenacin. Utility values for the calculation of
Quality Adjusted Life Years (QALYs) were taken from published
sources. The analysis included costs directly associated with OAB
treatment, i.e. antimuscarinic therapy, GP consultations and out-
patient contacts; cost data were taken from NHS published
sources (2007/2008 prices). Resource utilisation was based on
expert opinion. RESULTS: In the base-case analysis, solifenacin
resulted in a cost-effective treatment strategy compared with
fesoterodine for urgency and frequency outcomes being both
more effective and less costly. Fesoterodine was more effective
but more expensive than solifenacin for incontinence, with an
ICER of £84,686/QALY. CONCLUSIONS: This analysis sug-
gests that fesoterodine does not provide a cost-effective treatment
option relative to solifenacin at a cost-effectiveness threshold of
£30,000/QALY for the resolution of urgency, frequency and
incontinence in patients treated for OAB.
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OBJECTIVES: At present, expanded criteria donors suppose up
to 40–50% of the renal transplant. The aim was to evaluate
cost-utility difference between standard criteria donors (SCD)
versus expanded criteria donors (ECD) at the ﬁrst year of kidney
transplant. METHODS: Patients were collected in the waiting-
list for renal transplant in our region from January 1, 2003 to
December 31, 2005. Clinical and demographic variables, trans-
plant costs and EQ-5D tariff, as a generic perceived state of
Abstracts A653
